### SESSION #1  **INFLAMMATION, CVD & CHF IN DM**  
**Chairs:** Robert R. Henry, MD • George Grunberger, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:10am</td>
<td>CME Questions</td>
<td>Ronald M. Krauss, MD</td>
</tr>
<tr>
<td>8:15am</td>
<td>Dietary Saturated Fats vs Carbohydrates Impact on CVD Risk</td>
<td>Javed Butler, MD</td>
</tr>
<tr>
<td>8:35am</td>
<td>State-of-the-Art: CHF in Diabetes 2018 Update</td>
<td>Sanjay Kaul, MD</td>
</tr>
<tr>
<td>9:00am</td>
<td>Has CANTOS Nailed the Inflammatory Hypothesis of Atherosclerosis?</td>
<td>Brendan M. Everett, MD</td>
</tr>
<tr>
<td>9:25am</td>
<td>Anti-Inflammatory Therapy for Cardiovascular Disease and Diabetes</td>
<td></td>
</tr>
<tr>
<td>9:45am – 10:05am</td>
<td>Q+A Panel Discussion &amp; Clinical Implications</td>
<td></td>
</tr>
<tr>
<td>10:05am – 10:35am</td>
<td>Refreshment Break at Exhibit Hall</td>
<td></td>
</tr>
</tbody>
</table>

### SESSION #2  **DIABETES**  
**Chairs:** Bart Staels, PhD • Derek LeRoith, MD, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:35am</td>
<td>We Can Stem the Diabetes Epidemic and Do It Adroitly; Here’s How</td>
<td>W. Timothy Garvey, MD</td>
</tr>
<tr>
<td>10:55am</td>
<td>Is there a Case for the Circadian Syndrome?</td>
<td>Paul Zimmet, AO, PhD</td>
</tr>
<tr>
<td>11:15am</td>
<td>Control of Endogenous Glucose Production</td>
<td>Richard N. Bergman, PhD</td>
</tr>
<tr>
<td>11:35am</td>
<td>The New Biology of Type 2 Diabetes</td>
<td>Gerald I. Shulman, MD, PhD</td>
</tr>
<tr>
<td>12:00pm – 12:20pm</td>
<td>Q+A Panel Discussion &amp; Clinical Implications</td>
<td></td>
</tr>
</tbody>
</table>

### SESSION #3  **THE METABOLIC SYNDROME REVISITED: A SALUTE TO GERALD REAVEN, MD**  
**Chairs:** Ralph A. DeFronzo, MD • Peter J. Grant, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30pm</td>
<td>Glucose Control and Vascular Disease: Is the Glass Half Empty or Half Full?</td>
<td>Peter Reaven, MD</td>
</tr>
<tr>
<td>1:55pm</td>
<td>Insulin Resistance in T2DM: Whole Body, Organ, Cellular, and Molecular Pathogenesis</td>
<td>Ralph A. DeFronzo, MD</td>
</tr>
<tr>
<td>2:20pm</td>
<td>Insulin Resistance: Molecular and Cardiovascular Implications</td>
<td>George L. King, MD</td>
</tr>
<tr>
<td>2:45pm</td>
<td>Insulin Resistance is a Physiologic Defense Against Metabolic Stress</td>
<td>Marc Prentki, PhD</td>
</tr>
<tr>
<td>3:10pm – 3:30pm</td>
<td>Q+A Panel Discussion &amp; Clinical Implications</td>
<td></td>
</tr>
<tr>
<td>3:30pm – 4:00pm</td>
<td>Refreshment Break at Exhibit Hall</td>
<td></td>
</tr>
</tbody>
</table>

### CONCURRENT SESSIONS  **MEET THE EXPERT**

- Daniel Einhorn, MD  *Diabetes Guidelines 2019 - A Guide for the Perplexed*
- Mikhail Kosiborod, MD  *CVD in Diabetes*
- Ralph A. DeFronzo, MD  *Insulin Resistance & Complications*
- Yehuda Handelsman, MD  *Lipids, Metabolism & the Heart*

### SESSION #4  **CV MANAGEMENT TODAY AND TOMORROW**  
**Chairs:** Robert Chilton, DO • Alan Sinaiko, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:00pm</td>
<td>New CV Outcome Trials</td>
<td>Mikhail Kosiborod, MD</td>
</tr>
</tbody>
</table>
| 5:30pm – 6:10pm | DEBATE: GLUCOSE MANAGEMENT HAS LITTLE IMPACT ON CVD IN DM | Darren McGuire, MD  

### THURSDAY, NOVEMBER 29, 2018

**7:00am – 8:00am**  
Registration & Continental Breakfast at Exhibit Hall

**8:00am – 8:10am**  
Welcome & Introduction  
Yehuda Handelsman, MD/ Chair

**SESSION #1**  **INFLAMMATION, CVD & CHF IN DM**  
Chairs: Robert R. Henry, MD • George Grunberger, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:10am</td>
<td>CME Questions</td>
<td>Ronald M. Krauss, MD</td>
</tr>
<tr>
<td>8:15am</td>
<td>Dietary Saturated Fats vs Carbohydrates Impact on CVD Risk</td>
<td>Javed Butler, MD</td>
</tr>
<tr>
<td>8:35am</td>
<td>State-of-the-Art: CHF in Diabetes 2018 Update</td>
<td>Sanjay Kaul, MD</td>
</tr>
<tr>
<td>9:00am</td>
<td>Has CANTOS Nailed the Inflammatory Hypothesis of Atherosclerosis?</td>
<td>Brendan M. Everett, MD</td>
</tr>
<tr>
<td>9:25am</td>
<td>Anti-Inflammatory Therapy for Cardiovascular Disease and Diabetes</td>
<td></td>
</tr>
<tr>
<td>9:45am – 10:05am</td>
<td>Q+A Panel Discussion &amp; Clinical Implications</td>
<td></td>
</tr>
<tr>
<td>10:05am – 10:35am</td>
<td>Refreshment Break at Exhibit Hall</td>
<td></td>
</tr>
</tbody>
</table>

**SESSION #2**  **DIABETES**  
Chairs: Bart Staels, PhD • Derek LeRoith, MD, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:35am</td>
<td>We Can Stem the Diabetes Epidemic and Do It Adroitly; Here’s How</td>
<td>W. Timothy Garvey, MD</td>
</tr>
<tr>
<td>10:55am</td>
<td>Is there a Case for the Circadian Syndrome?</td>
<td>Paul Zimmet, AO, PhD</td>
</tr>
<tr>
<td>11:15am</td>
<td>Control of Endogenous Glucose Production</td>
<td>Richard N. Bergman, PhD</td>
</tr>
<tr>
<td>11:35am</td>
<td>The New Biology of Type 2 Diabetes</td>
<td>Gerald I. Shulman, MD, PhD</td>
</tr>
<tr>
<td>12:00pm – 12:20pm</td>
<td>Q+A Panel Discussion &amp; Clinical Implications</td>
<td></td>
</tr>
</tbody>
</table>

**SESSION #3**  **THE METABOLIC SYNDROME REVISITED: A SALUTE TO GERALD REAVEN, MD**  
Chairs: Ralph A. DeFronzo, MD • Peter J. Grant, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30pm</td>
<td>Glucose Control and Vascular Disease: Is the Glass Half Empty or Half Full?</td>
<td>Peter Reaven, MD</td>
</tr>
<tr>
<td>1:55pm</td>
<td>Insulin Resistance in T2DM: Whole Body, Organ, Cellular, and Molecular Pathogenesis</td>
<td>Ralph A. DeFronzo, MD</td>
</tr>
<tr>
<td>2:20pm</td>
<td>Insulin Resistance: Molecular and Cardiovascular Implications</td>
<td>George L. King, MD</td>
</tr>
<tr>
<td>2:45pm</td>
<td>Insulin Resistance is a Physiologic Defense Against Metabolic Stress</td>
<td>Marc Prentki, PhD</td>
</tr>
<tr>
<td>3:10pm – 3:30pm</td>
<td>Q+A Panel Discussion &amp; Clinical Implications</td>
<td></td>
</tr>
<tr>
<td>3:30pm – 4:00pm</td>
<td>Refreshment Break at Exhibit Hall</td>
<td></td>
</tr>
</tbody>
</table>

### CONCURRENT SESSIONS  **MEET THE EXPERT**

- Daniel Einhorn, MD  *Diabetes Guidelines 2019 - A Guide for the Perplexed*
- Mikhail Kosiborod, MD  *CVD in Diabetes*
- Ralph A. DeFronzo, MD  *Insulin Resistance & Complications*
- Yehuda Handelsman, MD  *Lipids, Metabolism & the Heart*

### SESSION #4  **CV MANAGEMENT TODAY AND TOMORROW**  
Chairs: Robert Chilton, DO • Alan Sinaiko, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:00pm</td>
<td>New CV Outcome Trials</td>
<td>Mikhail Kosiborod, MD</td>
</tr>
</tbody>
</table>
| 5:30pm – 6:10pm | DEBATE: GLUCOSE MANAGEMENT HAS LITTLE IMPACT ON CVD IN DM | Darren McGuire, MD  

### 6:30PM – 7:30PM WELCOME AND POSTERS RECEPTION

**DINNER SYMPOSIUM**  **CME**  
Supported by an Education Grant from: ASTRAZENECA

- Biykem Bozkurt, MD, PhD
- Matthew R. Weir, MD
- Mikhail Kosiborod, MD
- Robert Chilton, DO

- Epidemiology of CHF in Diabetes Differentiating HFrEF and HfPEF
- The Role of the Kidney in CHF: The Cardio-Renal Syndrome
- Diabetes CVOT Impact on CHF in Diabetes
- The Contemporary Approach to the Management of CHF in DM & Non-DM Panel and Q&A — The Future of the Diagnosis and Management of CHF.
Registration & Coffee at Exhibit Hall

6:00am – 8:00am

PRODUCT THEATER  Non CME  Full Breakfast will be Provided

Jardiance® (empagliflozin) tablets: Evolving Clinical Development
Supported By: BOEXERINGER INGLEHEIM / LILLY USA

Matthew Budoff, MD  James R. Gavin III MD, PhD

7:50am – 8:00am

SESSION #5  LIPIDS MANAGEMENT GOALS & COMPLICATIONS

Chairs: Ronald M. Krauss, MD  •  Paul S. Jellinger, MD

8:00am

8:05am

8:25am – 9:05am

DEBATE: THE BIG LDL DEBATE FURTHER TREATMENT BENEFIT:
A) MOSTLY WHEN BASELINES LDL-C > 100; B) THE LOWER GOAL LDL-C THE BETTER

YES / NO  Jennifer G. Robinson, MD

NO / YES  Sergio Fazio, MD, PhD

9:05am

Understanding How Statins Cause Increased Risk of Diabetes

Joshua W. Knowles, MD, PhD

9:25am – 9:45am

Q+A Panel Discussion & Clinical Implications

SESSION #6  DIABETES & CVD IN THE DEVELOPING YEARS

Chairs: Paul Zimmet, AO, PhD  •  Mikhail Kosiborod, MD

9:45am

Obesity and Cardiovascular Disease in Children and Adolescents

Stephen R. Daniels, MD, PhD

10:05am – 10:35am

Refreshment Break at Exhibit Hall

10:35am

Early Treatment of Youth Onset T2D with Metformin or Insulin Failed to Restore Beta Cell Function:
Lessons from the RISE-Pediatric Medication Study

Sonia Caprio, MD

Relation of Childhood Cardiovascular Risk Factors to Adult Cardiovascular Disease

Alan Sinaiko, MD

11:15am – 11:30am

Q+A Panel Discussion & Clinical Implications

SESSION #7  INSULIN RESISTANCE AND DIABETES

Chairs: Daniel Einhorn, MD  •  Tracey L. McLaughlin, MD

11:30am

Insulin Resistance in Health and Disease

Peter J. Grant, MD

11:50am

Adapting to Insulin Resistance in Obesity: Role of Insulin Secretion and Clearance

Sun H. Kim, MD

12:10pm

The Relationship of Diabetes, Metabolism & Aging

Derek LeRoith, MD, PhD

12:30pm

FGF1 – Resetting Diabetes

Ronald M. Evans, PhD

12:50pm – 1:05pm

Q+A Panel Discussion & Clinical Implications

SESSION #8  PERSONALIZED MEDICINE – APPETITE THE GUT & THE MICROBIOME

Chairs: Samuel Klein, MD  •  Sonia Caprio, MD

2:00pm

Bile Acids: Signaling Molecules Connecting the Gut to the Liver in Metabolic Control

Bart Staels, PhD

2:20pm

Personalized Nutrition for Diabetes Based on Gut Microbiome and Clinical Data

Eran Segal, PhD

2:40pm

TMAO Update

Ronald M. Krauss, MD

3:00pm

Mechanisms Regulating Appetite and Weight in Humans: An Update

Christos Mantzoros, MD, DSc, PhD

3:20 pm – 3:40pm

Q+A Panel Discussion & Clinical Implications

SESSION #9  THE STATE OF DIABETES & CVD

Chairs: Christian Mende, MD  •  Phillip Levy, MD

3:40pm

The State of Obesity and Diabetes in China and Impact on CVD

Guang Ning, MD, PhD

4:00PM - 4:30PM  Refreshment Break at Exhibit Hall

4:30pm

Diabetes with ASCVD in Latin America: Is it all the same?

Jaime A. Davidson, MD

4:50pm

Q+A Panel Discussion & Clinical Implications

SESSION #10  WHAT’S IN THE PIPELINE?  Non CME

Chairs: Ralph A. DeFronzo, MD  •  Christos Mantzoros, MD, DSc, PhD

5:00pm

AZ / MedImmune

Booz Hirshberg, MD

5:15pm

Gilead

C. Stephen Djedjos, MD

5:30pm

Lilly

Leonard C. Glass, MD

5:45pm

Novo Nordisk

Todd Hobbs, MD

6:00pm

Amgen

Scott M. Wasserman, MD

6:15pm – 6:30pm

Q+A Panel Discussion & Clinical Implications & Post-CME Questions

FRIDAY, NOVEMBER 30, 2018

6:00am – 8:00am  Registration & Coffee at Exhibit Hall

6:45am – 7:45am  PRODUCT THEATER  Non CME  Full Breakfast will be Provided

Jardiance® (empagliflozin) tablets: Evolving Clinical Development
Supported By: BOEXERINGER INGLEHEIM / LILLY USA

Matthew Budoff, MD  James R. Gavin III MD, PhD

7:50am – 8:00am  Summary of First Day

Zachary T. Bloomgarden, MD

SESSION #5  LIPIDS MANAGEMENT GOALS & COMPLICATIONS

Chairs: Ronald M. Krauss, MD  •  Paul S. Jellinger, MD

8:00am

Pre CME Questions

Norman E. Lepor, MD

8:05am

Lessons From the PCSK9i Outcome Trials

Norman E. Lepor, MD

8:25am – 9:05am

DEBATE: THE BIG LDL DEBATE FURTHER TREATMENT BENEFIT:
A) MOSTLY WHEN BASELINES LDL-C > 100; B) THE LOWER GOAL LDL-C THE BETTER

YES / NO  Jennifer G. Robinson, MD

NO / YES  Sergio Fazio, MD, PhD

9:05am

Understanding How Statins Cause Increased Risk of Diabetes

Joshua W. Knowles, MD, PhD

9:25am – 9:45am

Q+A Panel Discussion & Clinical Implications

SESSION #6  DIABETES & CVD IN THE DEVELOPING YEARS

Chairs: Paul Zimmet, AO, PhD  •  Mikhail Kosiborod, MD

9:45am

Obesity and Cardiovascular Disease in Children and Adolescents

Stephen R. Daniels, MD, PhD

10:05am – 10:35am

Refreshment Break at Exhibit Hall

10:35am

Early Treatment of Youth Onset T2D with Metformin or Insulin Failed to Restore Beta Cell Function:
Lessons from the RISE-Pediatric Medication Study

Sonia Caprio, MD

Relation of Childhood Cardiovascular Risk Factors to Adult Cardiovascular Disease

Alan Sinaiko, MD

11:15am – 11:30am

Q+A Panel Discussion & Clinical Implications

SESSION #7  INSULIN RESISTANCE AND DIABETES

Chairs: Daniel Einhorn, MD  •  Tracey L. McLaughlin, MD

11:30am

Insulin Resistance in Health and Disease

Peter J. Grant, MD

11:50am

Adapting to Insulin Resistance in Obesity: Role of Insulin Secretion and Clearance

Sun H. Kim, MD

12:10pm

The Relationship of Diabetes, Metabolism & Aging

Derek LeRoith, MD, PhD

12:30pm

FGF1 – Resetting Diabetes

Ronald M. Evans, PhD

12:50pm – 1:05pm

Q+A Panel Discussion & Clinical Implications

SESSION #8  PERSONALIZED MEDICINE – APPETITE THE GUT & THE MICROBIOME

Chairs: Samuel Klein, MD  •  Sonia Caprio, MD

2:00pm

Bile Acids: Signaling Molecules Connecting the Gut to the Liver in Metabolic Control

Bart Staels, PhD

2:20pm

Personalized Nutrition for Diabetes Based on Gut Microbiome and Clinical Data

Eran Segal, PhD

2:40pm

TMAO Update

Ronald M. Krauss, MD

3:00pm

Mechanisms Regulating Appetite and Weight in Humans: An Update

Christos Mantzoros, MD, DSc, PhD

3:20 pm – 3:40pm

Q+A Panel Discussion & Clinical Implications

SESSION #9  THE STATE OF DIABETES & CVD

Chairs: Christian Mende, MD  •  Phillip Levy, MD

3:40pm

The State of Obesity and Diabetes in China and Impact on CVD

Guang Ning, MD, PhD

4:00PM - 4:30PM  Refreshment Break at Exhibit Hall

4:30pm

Diabetes with ASCVD in Latin America: Is it all the same?

Jaime A. Davidson, MD

4:50pm

Q+A Panel Discussion & Clinical Implications

SESSION #10  WHAT’S IN THE PIPELINE?  Non CME

Chairs: Ralph A. DeFronzo, MD  •  Christos Mantzoros, MD, DSc, PhD

5:00pm

AZ / MedImmune

Booz Hirshberg, MD

5:15pm

Gilead

C. Stephen Djedjos, MD

5:30pm

Lilly

Leonard C. Glass, MD

5:45pm

Novo Nordisk

Todd Hobbs, MD

6:00pm

Amgen

Scott M. Wasserman, MD

6:15pm – 6:30pm

Q+A Panel Discussion & Clinical Implications & Post-CME Questions

6:30PM – 8:00PM  ABSTRACT – ORAL PRESENTATION

Zachary T. Bloomgarden, MD Chair  •  Phillip Levy, MD  •  Daniel Einhorn, MD  •  George Grunberger, MD

Abstracts are published in “Endocrine Practice”, the official journal of the AACE | Editor in Chief: Derek LeRoith, MD, PhD
# SESSION #11
**MANAGEMENT OF DM & CVD**
Chairs: Yehuda Handelsman, MD • Peter J. Grant, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00am</td>
<td>Pre CME Questions</td>
<td>Vivian A. Fonseca, MD</td>
</tr>
<tr>
<td>8:05am</td>
<td>BRAVO — At Last, a Dynamic Risk Engine for America</td>
<td>David D’Alessio, MD</td>
</tr>
<tr>
<td>8:25am</td>
<td>New ADA/EASD Practice Recommendations</td>
<td>Michael Miller, MD</td>
</tr>
<tr>
<td>8:45am</td>
<td>ACC/AHA Lipids &amp; ASCVD Guidelines 2018 Update</td>
<td></td>
</tr>
<tr>
<td>9:05am</td>
<td>Q+A Panel Discussion &amp; Clinical Implications</td>
<td></td>
</tr>
</tbody>
</table>

# SESSION #12
**FAT OBESITY & METABOLISM**
Chairs: Vivian A. Fonseca, MD • W. Timothy Garvey, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:25am</td>
<td>&quot;Gerald Reaven Distinguished Leader in Insulin Resistance&quot;</td>
<td>Philipp E. Scherer, PhD</td>
</tr>
<tr>
<td>9:55am</td>
<td>Are There Clinically Important Weight Loss-Independent Metabolic Benefits of Gastrointestinal Bypass Surgery?</td>
<td>Samuel Klein, MD</td>
</tr>
<tr>
<td>10:15am</td>
<td><strong>Refreshment Break at Exhibit Hall</strong></td>
<td></td>
</tr>
<tr>
<td>10:35am</td>
<td>Sex and the Fat Cell</td>
<td>Tracey L. McLaughlin, MD</td>
</tr>
<tr>
<td>10:55am</td>
<td>Obesity &amp; Insulin Resistance in T1D - Clinical Implications</td>
<td>Richard E. Pratley, MD</td>
</tr>
<tr>
<td>11:15am</td>
<td>Q+A Panel Discussion &amp; Clinical Implications</td>
<td></td>
</tr>
</tbody>
</table>

# SESSION #13
**CONTEMPORARY APPROACH TO NAFLD/NASH**
Chairs: Jaime A. Davidson, MD • Christos Mantzoros, MD, DSc, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:35am</td>
<td>2018 Diagnostic Tools for Fatty Liver Disease and NASH</td>
<td>Arun J. Sanyal, MBBS, MD</td>
</tr>
<tr>
<td>11:55am</td>
<td>An Overview of Medications for NASH</td>
<td>Bart Staels, PhD</td>
</tr>
<tr>
<td>12:15pm</td>
<td>Q+A Panel Discussion &amp; Clinical Implications</td>
<td></td>
</tr>
</tbody>
</table>

# SESSION #14
**THE KIDNEY & THE HEART**
Chairs: Zachary T. Bloomgarden, MD • Daniel Einhorn, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30pm</td>
<td>Obesity, Insulin Resistance and Kidney Disease</td>
<td>Matthew R. Weir, MD</td>
</tr>
<tr>
<td>1:50pm</td>
<td>The Cardiorenal Syndrome</td>
<td>Peter A. McCullough, MD</td>
</tr>
<tr>
<td>2:10pm</td>
<td><strong>DEBATE: SHOULD PATIENTS WITH DIABETES &amp; ESTABLISHED CARDIOVASCULAR DISEASE</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>GET AN SGLT2i OR GLP1-RA?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>GLP1-RA</td>
<td>Mansoor Husain, MD</td>
</tr>
<tr>
<td></td>
<td>SGLT2i</td>
<td>Sunder Maudaliar, MD</td>
</tr>
<tr>
<td>2:50pm</td>
<td>The Fatty Kidney</td>
<td>Christian Mende, MD</td>
</tr>
<tr>
<td>3:10pm</td>
<td>The Fatty Heart</td>
<td>Robert J. Chilton, DO</td>
</tr>
<tr>
<td>3:30pm</td>
<td>Q+A Panel Discussion &amp; Clinical Implications &amp; CME Post Questions</td>
<td></td>
</tr>
</tbody>
</table>

## CONCURRENT SESSIONS
**CLINICAL WORKSHOPS**
Refreshments will be served

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:05pm</td>
<td>Diabetes</td>
<td>Philip Levy, MD • George Grunberger, MD</td>
</tr>
<tr>
<td>4:25pm</td>
<td>Lipids</td>
<td>Paul S. Jellinger, MD • Paul D. Rosenblit, MD, PhD</td>
</tr>
<tr>
<td>4:45pm</td>
<td>CHF</td>
<td>Robert J. Chilton, DO</td>
</tr>
<tr>
<td>5:05pm</td>
<td>Hypertension</td>
<td>Zachary T. Bloomgarden, MD</td>
</tr>
</tbody>
</table>

5:00pm Adjourn